Researchers at Georgetown Lombardi Comprehensive Cancer Center in Washington report using a new chip -- called DMET for drug-metabolizing enzymes -- to look for hundreds of mutations in as many as 170 genes.
A test unveiling genetic variations that correlate with drug effectiveness and toxicity is needed so the genetic variations -- specifically genes that encode proteins that impact how a drug is metabolized or taken in by the cells -- can be taken into account.
"This type of turn-key testing, if validated, could eventually replace highly-specialized, time-consuming and labor-intensive testing -- thus allowing more institutes the opportunity to pursue genotyping and pharmocogenetic research," John Deeken says in a statement.
Deeken and colleagues report their results testing the genotyping platform DMET in The Pharmacogenomics Journal.
"DMET appears to offer great promise in this field as a reliable test unveiling genetic variations that correlated with drug effectiveness and toxicity," Deeken says in a statement. "Still, DMET isn't yet ready for prime time in terms of having received Food and Drug Administration approval, but we're getting closer."
Exploding whale video goes viral on Internet
Wisconsin business offering 'therapeutic cuddling' forced to close